Published in Clin Lipidol on April 01, 2010
Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev (2011) 1.67
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev (2011) 0.91
An eicosanoid-centric view of atherothrombotic risk factors. Cell Mol Life Sci (2012) 0.84
Aspirin: pharmacology and clinical applications. Thrombosis (2011) 0.83
Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif. J Lipid Res (2013) 0.80
Heme Oxygenase-1 Promotes Delayed Wound Healing in Diabetic Rats. J Diabetes Res (2015) 0.77
Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists. ACS Med Chem Lett (2014) 0.76
Thromboxane A(2) receptor stimulation promotes closure of the rat ductus arteriosus through enhancing neointima formation. PLoS One (2014) 0.76
Targeting brain microvascular endothelial cells: a therapeutic approach to neuroprotection against stroke. Neural Regen Res (2015) 0.75
Effects of Aspirin on Endothelial Function and Hypertension. Curr Hypertens Rep (2016) 0.75
Acute effects of prostaglandin E1 and E2 on vascular reactivity and blood flow in situ in the chick chorioallantoic membrane. Prostaglandins Leukot Essent Fatty Acids (2012) 0.75
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med (2005) 6.32
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA (2009) 5.66
Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A (1975) 4.92
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev (2004) 4.41
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A (1993) 3.93
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 3.88
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg (2003) 2.91
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Isoprostanes: markers and mediators of oxidative stress. FASEB J (2004) 2.83
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. J Biol Chem (1995) 2.41
Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med (1998) 2.32
Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature (1991) 2.26
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Why there are two cyclooxygenase isozymes. J Clin Invest (2001) 2.13
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol (2005) 2.13
Activation of platelet function through G protein-coupled receptors. Circ Res (2006) 2.13
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest (2004) 2.12
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 2.11
Prostanoids in health and disease. J Lipid Res (2008) 2.06
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest (2006) 2.03
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins (1978) 1.85
Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation (1999) 1.79
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78
G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A (1994) 1.77
The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem (1990) 1.72
COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res (2003) 1.72
Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther (2008) 1.72
Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension (2004) 1.57
Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev (2005) 1.57
Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet (1990) 1.56
Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc Natl Acad Sci U S A (1985) 1.55
A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell (2003) 1.54
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A (2006) 1.52
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov (2007) 1.52
Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation (2001) 1.51
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation (2008) 1.50
Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A (2002) 1.48
Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol (1991) 1.48
Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem (1994) 1.46
Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation (2003) 1.43
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation (2005) 1.40
Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res (1999) 1.40
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A (2002) 1.39
Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem (2004) 1.38
COX-2-derived prostacyclin modulates vascular remodeling. Circ Res (2005) 1.37
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A (1986) 1.35
Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem (2000) 1.32
The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther (1997) 1.31
Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest (1994) 1.23
Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation (1997) 1.23
Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest (1983) 1.21
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation (2000) 1.21
Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem (2005) 1.16
Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest (1996) 1.13
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun (2000) 1.12
Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem (1999) 1.12
Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. Am J Physiol Heart Circ Physiol (2008) 1.11
Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun (1992) 1.11
Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. Role of serotonin, thromboxane A2, and adenine nucleotides. J Clin Invest (1986) 1.10
G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008) 1.10
Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem (1996) 1.10
Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) (1986) 1.10
Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension (1995) 1.09
Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol (2008) 1.08
Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem (1999) 1.07
Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther (2008) 1.07
Actions of nitric oxide on the release of prostacyclin from bovine endothelial cells in culture. Eur J Pharmacol (1988) 1.07
Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol (2003) 1.06
The intracellular trafficking of the G protein-coupled receptor TPbeta depends on a direct interaction with Rab11. J Biol Chem (2005) 1.06
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis (2008) 1.05
Role of the differentially spliced carboxyl terminus in thromboxane A2 receptor trafficking: identification of a distinct motif for tonic internalization. J Biol Chem (2000) 1.05
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes (2006) 1.05
The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem (2000) 1.05
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther (2007) 1.04
Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol (1998) 1.04
A role for the thromboxane receptor in L-NAME hypertension. Am J Physiol Renal Physiol (2008) 1.02
Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation (1986) 1.02
Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res (2008) 1.01
Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res (2004) 1.01
Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem (1999) 1.00
Retracted The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for nitric oxide-mediated desensitization. Independent modulation of Tp alpha signaling by nitric oxide and prostacyclin. J Biol Chem (2003) 1.00
Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J Clin Invest (1996) 0.99